ZTS

ZTS

USD

Zoetis Inc. Class A Common Stock

$119.830-0.600 (-0.498%)

Precio en Tiempo Real

Healthcare
Drug Manufacturers - Specialty & Generic
Estados Unidos

Gráfico de Precios

Loading Chart...

Métricas Clave

Métricas de Mercado
Fundamentos de la Empresa
Estadísticas de Negociación

Métricas de Mercado

Apertura

$120.430

Máximo

$121.310

Mínimo

$118.520

Volumen

8.35M

Fundamentos de la Empresa

Capitalización de Mercado

52.8B

Industria

Drug Manufacturers - Specialty & Generic

País

United States

Estadísticas de Negociación

Volumen Promedio

3.12M

Bolsa

NYQ

Moneda

USD

Rango de 52 Semanas

Mínimo $117.26Actual $119.830Máximo $181.85

Noticias Relacionadas

Analyst Upgrades

Morgan Stanley Maintains Overweight on Zoetis, Lowers Price Target to $175

Morgan Stanley analyst Erin Wright maintains Zoetis with a Overweight and lowers the price target from $211 to $175.

Ver más
Morgan Stanley Maintains Overweight on Zoetis, Lowers Price Target to $175
Analyst Upgrades

Zoetis Stock Outlook Clouded By Rising Competitive Pressures

Zoetis tops Q3 earnings estimates but trims 2025 sales forecast as companion animal growth slows and competition weighs on its outlook.

Ver más
Zoetis Stock Outlook Clouded By Rising Competitive Pressures
BusinessWire

Zoetis Announces Retirement of Rob Polzer at the End of 2025 and the Appointment of Kevin Esch as President of Research & Development for World Leader in Animal Health Beginning in 2026

Dr. Rob Polzer to Retire at the End of the Year After 10-Year Distinguished Career of Advancing Veterinary Medicine and Innovation Zoetis Inc. (NYSE:ZTS) today announced that following a 10-year distinguished career

Ver más
Zoetis Announces Retirement of Rob Polzer at the End of 2025 and the Appointment of Kevin Esch as President of Research & Development for World Leader in Animal Health Beginning in 2026
BusinessWire

Zoetis Receives European Commission Marketing Authorization for Portela® (relfovetmab) to Alleviate Pain Associated with Osteoarthritis in Cats

Zoetis Inc. today announced that the European Commission has granted the company marketing authorization for Portela® (relfovetmab), making it the first monoclonal antibody (mAb) therapy with a three-month dosing

Ver más
Zoetis Receives European Commission Marketing Authorization for Portela® (relfovetmab) to Alleviate Pain Associated with Osteoarthritis in Cats
BusinessWire

Zoetis Appoints Stephanie Tilenius to its Board of Directors

Health entrepreneur brings her digital and artificial intelligence (AI) experience to Zoetis Board Zoetis Inc. (NYSE:ZTS) today announced the appointment of Stephanie Tilenius to its Board of Directors, effective as

Ver más
Zoetis Appoints Stephanie Tilenius to its Board of Directors

Mantente Actualizado

Configura alertas de precio, recibe actualizaciones de análisis de IA y noticias de mercado en tiempo real.